Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study.
Giron-Hernandez C, Han JH, Alberio R, Singh A, García-Portilla MP, Pompili M, Knight RK, Richarz U, Gopal S, Antunes J. Giron-Hernandez C, et al. Among authors: knight rk. Neuropsychiatr Dis Treat. 2023 Apr 13;19:895-906. doi: 10.2147/NDT.S400342. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37077705 Free PMC article.
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.
Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Najarian D, et al. Among authors: knight rk. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028. Int J Neuropsychopharmacol. 2023. PMID: 37480362 Free PMC article. Clinical Trial.
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia.
Turkoz I, Wong J, Chee B, Siddiqui U, Knight RK, Richarz U, Correll CU. Turkoz I, et al. Among authors: knight rk. Ther Adv Psychopharmacol. 2023 Sep 29;13:20451253231200258. doi: 10.1177/20451253231200258. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37786804 Free PMC article.
Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations.
Turkoz I, Daskiran M, Siddiqui U, Knight RK, Johnston KL, Correll CU. Turkoz I, et al. Among authors: knight rk. Int J Neuropsychopharmacol. 2024 Feb 1;27(2):pyad067. doi: 10.1093/ijnp/pyad067. Int J Neuropsychopharmacol. 2024. PMID: 38300235 Free PMC article. Clinical Trial.
76 results